Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial

Abstract

A non-negligible number of men with PSA 1.8-3ng/ml have clinically significant PC. Whether a delay in the diagnosis of these tumors until they reached PSA ≥3ng/ml would impair their chance of cure remains to be evaluated.